GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study

1

By Bhanvi Satija and Sneha S K MADRID, Oct 26 (Reuters) – An experimental drug for a hard-to-treat bone cancer, being developed by Hansoh Pharmaceutical and GSK, helped patients live longer without

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)